Alterity Therapeutics Ltd (ASX:ATH) Share Price

Company Profile

Business description
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson’s disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
Contact
350 Collins Street
Suite 4, Level 14
MelbourneVIC3000
AUS
T: +61 393494906
E: [email protected]
https://www.alteritytherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
9

Recommended

We raise our fair value estimate for Oracle stock.

Luke Yang, CFA | 12 March 2026

Both high-dividend stocks and dividend-growth stocks are outperforming amid AI disruption.

Dan Lefkovitz | 12 March 2026

Is the economy and investor portfolios at risk from a potential ‘bank run’ in private credit?

Mark LaMonica, CFA | 12 March 2026

Index	Last price	Change	% Change
All Ordinaries	8,839.10	26.30	0.30%
CAC 40	7,911.53	145.83	-1.81%
DAX 40	23,447.29	142.36	-0.60%
Dow JONES (US)	46,558.47	119.38	-0.26%
FTSE 100	10,261.15	44.00	-0.43%
HKSE	25,465.60	251.16	-0.98%
NASDAQ	22,105.36	206.62	-0.93%
Nikkei 225	53,819.61	633.35	-1.16%
NZX 50 Index	13,187.34	11.95	-0.09%
S&P 500	6,632.19	40.43	-0.61%
S&P/ASX 200	8,617.10	29.20	0.34%
SSE Composite Index	4,095.45	33.65	-0.82%